Peptide YY: A new strategy for the treatment of obesity;Péptido YY: una nueva estrategia para el tratamiento de la obesidad

Endocrinologia y Nutricion

Volumn 56, Issue 1, 2009, Pages 1-3

  Giménez Palop, Olga ^a   Caixàs, Assumpta ^a  

^a HOSPITAL DE SABADELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GHRELIN; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST; PEPTIDE YY; PEPTIDE YY [3-36]; PROOPIOMELANOCORTIN;

APPETITE; ARCUATE NUCLEUS; CALORIC INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENERGY BALANCE; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GASTRIC BANDING; GLUCOSE HOMEOSTASIS; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRADER WILLI SYNDROME; PROTEIN EXPRESSION; SATIETY; STOMACH BYPASS; VAGUS NERVE; WEIGHT REDUCTION;

ANIMALS; BARIATRIC SURGERY; ENERGY INTAKE; FASTING; GHRELIN; HUMANS; INSULIN RESISTANCE; MICE; OBESITY; PEPTIDE YY; POSTPRANDIAL PERIOD; RATS; RECEPTORS, GASTROINTESTINAL HORMONE; SATIATION;

EID: 60949088326     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)70186-X     Document Type: Editorial

References (32)

1. Conlon J.M. The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP). Peptides 23 (2002) 269-278
2. Tatemoto K., Carlquist M., and Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296 (1982) 659-660
3. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., and Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89 (1985) 1070-1077
4. Eberlein G.A., Eysselein V.E., Schaeffer M., Layer P., Grandt D., Goebell H., et al. A new molecular form of PYY: structural characterization of human PYY (3-36) and PYY (1-36). Peptides 10 (1989) 797-803
5. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51 (1994) 151-159
6. Adrian T.E., Savage A.P., Sagor G.R., Allen J.M., Bacarese-Hamilton A.J., Tatemoto K., et al. Effect of peptide YY on gastric pancreatic, and biliary function in humans. Gastroenterology 89 (1985) 494-499
7. Ekblad E., and Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 146 (2002) 879-888
8. Naveilhan P., Neveu I., Arenas E., and Ernfors P. Complementary and overlapping expression of Y1, Y2 and Y5 receptors in the developing and adult mouse nervous system. Neuroscience 87 (1998) 289-302
9. Parker R.M., and Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 11 (1999) 1431-1448
10. Larhammar D. Structural diversity of receptors for neuropeptide, peptide YY and pancreatic polypeptide. Regul Pept 65 (1996) 165-174
11. Blomqvist A.G., and Herzog H. Y-receptor subtypes-how many more?. Trends Neurosci 20 (1997) 294-298
12. Koda S., Date Y., Murakami N., Shimbara T., Hanada T., Toshinai K., et al. The role of the vagal nerve in peripheral PYY3-36 induced feeding reduction in rats. Endocrinology 146 (2005) 2369-2375
13. Essah P.A., Levy J.R., Sistrun S.N., Kelly S.M., and Nestler J.E. Effect of macronutrient composition on postprandial peptide YY levels. J Clin Endocrinol Metab 92 (2007) 4052-4055
14. Wyne K., Stanley S., and Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 89 (2004) 2576-2582
15. Penín M., Pérez Fontán M., García Buela J., Isidro M.L., Martínez T., Outeiriño E., et al. Respuesta secretora de PYY1-36 y PYY3-36 tras una comida mixta en sujetos normales. Endocrinol Nutr 55 (2008) 333-339
16. Schwartz M.W., and Morton G.J. Obesity: keeping hunger at bay. Nature 418 (2002) 595-597
17. Ueno H., Yamaguchi H., Mizuta M., and Nakazato M. The role of PYY in feeding regulation. Regul Pept 145 (2008) 12-16
18. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418 (2002) 650-654
19. Broberger C., Landry M., Wong H., Walsh J.N., and Hokfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in proopiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 66 (1997) 393-408
20. Corp E.S., McQuade J., Krasnicki S., and Conze D.B. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides 22 (2001) 493-499
21. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptordeficient, and Y5 receptor-deficient mice. Endocrinology 141 (2000) 1011-1016
22. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Whiters D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (2003) 941-948
23. Giménez-Palop O., Giménez-Pérez G., Mauricio D., González-Clemente J.M., Potau N., Berlanga E., et al. A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin Endocrinol 66 (2007) 198-204
24. Roth C.L., Enriori P.J., Harz K., Woelfle J., Cowley M.A., and Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 90 (2005) 6386-6391
25. Rodieux F., Giusti V., D'Alessio D.A., Suter M., and Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 16 (2008) 298-305
26. Morínigo R., Vidal J., Lacy A.M., Delgado S., Casamitjana R., and Gomis R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg 247 (2008) 270-275
27. Boey D., Heilbronn L., Laybutt D.R., Kriketos A.D., Herzog H., and Campbell L.V. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides 40 (2006) 317-324
28. Viardot A., Heilbronn L.K., Herzog H., Gregersen S., and Campbell L.V. Abnormal postprandial PYY response in insulin sensitive nondiabetic subjects with a strong family history of type 2 diabetes. Int J Obes 32 (2008) 943-948
29. Sloth B., Davidsen L., Holst J.J., Flint A., and Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 293 (2007) E604-E609
30. Gantz I., Erondu N., Mallick M., Musser B., Krishna R., Tanaka W.K., et al. Efficay and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92 (2007) 1754-1757
31. Ortiz A.A., Milardo L.F., DeCarr L.B., Buckholz T.M., Mays M.R., Claus T.H., et al. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J Pharmacol Exp Ther 323 (2007) 692-700
32. Unniappan S., McIntosh C.H., Demuth H.U., Heiser U., Wolf R., and Kieffer T.J. Effects of dipeptidyl peptidase IV on satiety actions of peptide YY. Diabetologia 49 (2006) 1915-1923